文献速递银屑病与炎症性皮肤病

银屑病治疗中的生物制剂转换:系统综述与荟萃分析

Biopharmaceutical Switching in Psoriasis Treatment: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Dermatol · 2025-08-06

转换后PASI 90等指标显著改善,安全性结局与基线无显著差异,但需警惕感染风险。

要点

  • 生物制剂转换可显著改善银屑病PASI 90应答。
  • 转换后严重不良事件及治疗相关不良事件风险未显著增加。
  • 抗TNF-α转换至抗IL-23p19等感染风险相对较高。

核心结论

  • 跨类生物制剂转换在显著比例的患者中有效。
  • 转换后需警惕感染风险。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase和Cochrane Library至2025年1月25日。

主要发现

  • 第4周与第0周相比,PASI 90的OR为6.53(95%CI 2.58-16.51)。
  • PASI 90的OR为28.61(95%CI 12.89-63.47),PASI 75的OR为11.11(95%CI 5.95-20.75),PASI 100的OR为18.76(95%CI 8.37-42.01)。
  • 严重不良事件OR为1.63(95%CI 0.72-3.69),严重AE OR为1.40(95%CI 0.61-3.26),治疗相关AE OR为1.79(95%CI 0.41-7.88)。
  • 从抗TNF-α转换至抗IL-23p19、抗IL-17A或抗IL-12/23p40的感染率分别为0.62%、0.54%和0.39%。

关键数值与推荐

  • 主要终点为PASI 90。
  • 次要终点包括PASI 75/100、研究者与医生整体评估0或1、体表面积≤1%、患者报告结局及安全性。

临床怎么用

  • 初始生物制剂治疗失败后可考虑跨类生物制剂转换。
  • 转换时需监测感染风险,尤其是从抗TNF-α转换至其他类别的患者。

局限性

  • 需更大患者队列和更长随访数据以得出更确凿结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with psoriasis may require a switch to another therapy due to high treatment costs, primary effectiveness failure, biologic fatigue, or adverse effects associated with the initial biologic treatment; however, the availability of evidence for the effectiveness and safety of interclass biologic switching for the treatment of psoriasis is unknown. OBJECTIVE: To investigate the effectiveness and safety of psoriasis treatment after the failure of initial biologic therapy, particularly when patients switch to a second biologic. DATA SOURCES: PubMed, Embase, and the Cochrane Library were searched from inception through January 25, 2025. STUDY SELECTION: The study included randomized clinical trials (RCTs) of patients with plaque psoriasis aged 18 years or older involving crossover or switching from 1 biologic agent to another initial biologic within the same or different drug class. DATA EXTRACTION AND SYNTHESIS: Two researchers independently screened the records and abstracted data using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Data were pooled using random-effects models. MAIN OUTCOMES AND MEASURES: The prespecified primary end point was psoriasis area and severity index (PASI) 90. Secondary end points included clinician- and patient-reported outcomes (PROMs) and safety. Clinical effectiveness was evaluated based on the PASI responses (PASI 75, 90, and 100) and the Investigator's and Physician's Global Assessments scores of 0 or 1 and body surface area of 1% or less. PROMs included the dermatology life quality index and psoriasis symptoms and signs diary. Safety concerns included adverse events (AEs), serious AEs, severe AEs, treatment-related AEs, and specific AEs. RESULTS: Twenty-four RCTs involving 12 661 patients with psoriasis and 8 switching categories were analyzed. Significant differences observed in PASI 90 between week 4 and week 0 (odds ratio [OR], 6.53; 95% CI, 2.58-16.51). Substantial disparities were noted across various PASI response metrics, specifically PASI 90 (OR, 28.61; 95% CI, 12.89-63.47), PASI 75 (OR, 11.11; 95% CI, 5.95-20.75), and PASI 100 (OR, 18.76; 95% CI, 8.37-42.01). No difference exists in safety outcomes between the end point and week 0, including in serious AEs (OR, 1.63; 95% CI, 0.72-3.69), severe AEs (OR, 1.40; 95% CI, 0.61-3.26), and treatment-related AEs (OR, 1.79; 95% CI, 0.41-7.88). The highest risk of infection was associated with switching from anti-TNF-α agents to anti-interleukin (IL)-23p19, anti-IL-17A, or anti-IL-12/23p40 agents, with infection rates of 0.62%, 0.54% and 0.39%, respectively. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis found that interclass biologic switching was effective in a significant number of patients. With the introduction of biologics with diverse mechanisms of action, these options may become viable and potentially superior. However, further confirmatory data from larger patient cohorts and longer follow-up periods are required to obtain more conclusive results. Our results highlight the importance of vigilance for infections when switching biologics.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Zhang M, Hong S, Wang Q, et al. Biopharmaceutical Switching in Psoriasis Treatment: A Systematic Review and Meta-Analysis. JAMA Dermatol. 2025. PMID: 40768223. doi:10.1001/jamadermatol.2025.2714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。